Answers are grounded in this paper and cite their sources.
Purpose: To compare the effects of lithium and valproate on the body composition of psychiatric patients. Methods: This prospective cohort study evaluated the effects of lithium and valproate on body composition. Twenty-eight patients with type I bipolar disorder aged 23-54 years who just had started monotherapy were recruited. Body weight, percent body fat (PBF), soft lean mass, body mass index (BMI), and total body water were measured at baseline, one month, and six months. Changes in the body composition parameters between patients taking lithium (n=14) versus valproate (n=14) were compared. Findings: Overall mean age of study participants was 37.21 (±8) years, and 53.5% of patients were female. Average body weight gains in the first month were 1.3 kg and 2.2 kg for the lithium and valproate groups, respectively (p-value = 0.042). Mean body weight gain in the six months compared to the baseline was only 0.6 kg for the lithium group, while it was 4.3 kg for the valproate group (p-value < 0.001). The average increase in PBF at six months among patients treated with lithium versus valproate was 0.07% versus 2.2% respectively (p-value = 0.018). Patients treated with lithium had a smaller increase in their BMI in the sixth month of the study compared to the valproate group, with a mean change of 0.2 versus 2.3 kg/m2, respectively (p-value = 0.019). Conclusions: Our findings suggest that in patients with type I bipolar disorder, valproate leads to greater weight gain, BMI, and increase in PBF compared to lithium.
No takes yet. Share an insight, caveat, or question.
Banihashem et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: